Is Wegovy Oral or Injectable? Understanding the Differences and Benefits

Last reviewed: July 2, 2026

Last updated: July 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Wegovy is now both. For its first four years it existed only as a once-weekly subcutaneous injection, but on December 22, 2025 the FDA approved Wegovy tablets, 25 mg, under NDA 218316, and the current prescribing information now covers both forms in a single document. They are not the same product with a different wrapper. The two forms carry different approved indications, different dosage strengths, different administration requirements and different supporting trials, and the choice between them is a clinical conversation rather than a preference setting.

What the Injection Is Approved To Do

Wegovy injection carries four indications in current labeling. It is indicated to reduce the risk of major adverse cardiovascular events, meaning cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, in adults with established cardiovascular disease and either obesity or overweight. It is indicated to reduce excess body weight and maintain weight reduction long term in adults and in pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. It is also indicated for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis, formerly known as nonalcoholic steatohepatitis, with moderate to advanced liver fibrosis.

The injection's labeled dosage forms include single-dose pens at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg and 7.2 mg, single-dose syringes through 2.4 mg, and a single-patient-use FlexTouch pen containing 9.6 mg in 3 mL that delivers four 2.4 mg doses. It is administered subcutaneously once weekly.

What the Tablet Is Approved To Do

Wegovy tablets carry a narrower set of indications. The tablet is indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.

Two things are absent from that list. The tablet does not carry the pediatric weight-management indication for patients aged 12 and older, and it does not carry the noncirrhotic MASH indication. If either of those is the clinical reason for treatment, the labeling points to the injection. The tablet's dosage forms are 1.5 mg, 4 mg, 9 mg and 25 mg, with a recommended maintenance dosage of 25 mg orally once daily.

Why an Oral GLP-1 Was Difficult to Build

Semaglutide is a peptide. The gastrointestinal tract is designed to break peptides down into amino acids, which is why insulin and most other peptide drugs have historically required injection. An oral semaglutide tablet only works because it is co-formulated with an absorption enhancer that creates a local environment in the stomach where a fraction of the drug survives and crosses into circulation.

That fraction is small, which is why the tablet's maintenance dosage is 25 mg daily while the injection's is 2.4 mg weekly. It also means absorption is fragile. The labeling requires the tablet be taken on an empty stomach in the morning with no more than about four ounces of plain water, swallowed whole rather than split, crushed, chewed or dissolved, with a wait of at least 30 minutes before food, other beverages or other oral medications. Those requirements exist because deviating from them changes how much drug is absorbed. The exact instructions for any individual prescription come from the pharmacy label and the prescriber, not from an article.

What the Trials Showed for Each Form

The injection's pivotal weight-management evidence is the 68-week STEP 1 trial, which enrolled 1,961 adults with a body mass index of 30 or greater, or 27 or greater with at least one weight-related coexisting condition, and without diabetes. Mean change in body weight from baseline to week 68 was −14.9% with once-weekly semaglutide 2.4 mg. A later phase 3b trial of the higher 7.2 mg dose, STEP UP, reported mean bodyweight change of −18.7% at 72 weeks versus −15.6% at 2.4 mg and −3.9% with placebo.

The tablet's pivotal evidence is OASIS 4, a 71-week randomized, double-blind, placebo-controlled trial in 307 adults without diabetes who had a BMI of 30 or higher, or 27 or higher with at least one obesity-related complication. Estimated mean change in body weight from baseline to week 64 was −13.6% with oral semaglutide 25 mg versus −2.2% with placebo, an estimated difference of −11.4 percentage points. These were separate trials with different durations and sample sizes, not a head-to-head comparison, so the percentages should be read as two independent results rather than as a ranking.

How the Two Forms Differ in Daily Practice

The injection is a once-weekly event. The tablet is a daily one with a fasting window attached, which suits some routines and not others. Neither pattern is inherently easier; a person who dislikes needles may find weekly injection harder than daily tablets, and a person with an irregular morning schedule may find the reverse.

Shared safety considerations do not change with the form. Both carry a boxed warning regarding thyroid C-cell tumors, and both carry labeled warnings covering pancreatitis, gallbladder disease, acute kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity, and pulmonary aspiration during general anesthesia or deep sedation. The route of administration changes the logistics, not the pharmacology.

Compounded Semaglutide Is a Separate Category Again

Compounded semaglutide, in any form, is not an FDA-approved finished product. The FDA states plainly that compounded drugs are not reviewed for safety, effectiveness or quality before they are marketed, and the agency has separately warned about salt forms of semaglutide, about products labeled for research use only that were sold to consumers with dosing instructions, and about counterfeit product found in the U.S. supply chain.

A compounded preparation is prepared by a licensed pharmacy pursuant to a prescription for an individual patient. It is not a generic version of Wegovy, because no approved generic exists, and describing it that way misstates its regulatory status.

Frequently Asked Questions

Is Wegovy oral or injectable?

Both, as of December 22, 2025, when the FDA approved Wegovy tablets at 25 mg under NDA 218316. Before that date Wegovy existed only as a once-weekly subcutaneous injection, approved under NDA 215256 on June 4, 2021. The current prescribing information covers both forms, but they carry different indications, different dosage strengths and different administration requirements, so they are two distinct products rather than two packages of the same one.

Do the Wegovy tablet and injection treat the same conditions?

Not entirely. Both are indicated for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and for long-term weight reduction in adults. Only the injection is indicated for weight reduction in pediatric patients aged 12 years and older with obesity, and only the injection is indicated for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis.

Why is the tablet 25 mg when the injection is 2.4 mg?

Semaglutide is a peptide, and the gastrointestinal tract breaks peptides down, so only a small fraction of an oral dose reaches circulation. The tablet is co-formulated with an absorption enhancer, but it still has to deliver far more drug to reach comparable exposure. That is why the tablet's maintenance dosage is 25 mg once daily while the injection's recommended maintenance dosage for weight reduction is 2.4 mg once weekly.

Does the tablet work as well as the injection?

The two have not been compared head to head in a single trial. In the 68-week STEP 1 trial, once-weekly injectable semaglutide 2.4 mg produced a mean body weight change of minus 14.9%. In the 71-week OASIS 4 trial, oral semaglutide 25 mg produced an estimated mean change of minus 13.6% at week 64 versus minus 2.2% with placebo. Different trials, different populations and durations, so these are parallel results rather than a ranking.

Are there special rules for taking the Wegovy tablet?

Yes. The labeling specifies that the tablet is taken on an empty stomach in the morning with no more than about four ounces of plain water, swallowed whole without splitting, crushing, chewing or dissolving, and followed by a wait of at least 30 minutes before food, other beverages or other oral medications. Those conditions exist because absorption is fragile. The exact instructions for your prescription come from the pharmacy label and your prescriber.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.